

Monoclonal Anti-Birch pollen allergen Bet v1 human antibody

Product reference: DDX0070-DDX0076


Description:

Birch pollen allergy is a frequent pathology with IgE reactivity against Betv1 the major birch pollen allergen. Human monoclonal antibodies secreting B cells have been cloned from PBMC of allergic patients. These high affinity human monoclonal antibodies raised against BetV1 inhibit the binding of IgE to nitrocellulose-blotted Bet v1 and inhibit histamine release by sensitized basophils. (Visco V. et al, *J. Immunol.*, 1996 ; 157: 956-962 ; Denépoux S et al, *FEBS Lett.* 2000 Jan 7;465(1):39-46.)

| | |
|--------------------------|---|
| Specificity: | birch pollen Bet v1 |
| Cross-reactivity: | large panel of tree's pollen |
| Source: | human B cells immortalized from a birch pollen allergic patient |
| Purification: | QMA Hyper-D Ion-exchange chromatography |
| Formulation/size: | Purified: 100 µg in 200 µl Tris-NaCl pH 8 Coupled: 100 µg in 200 µl PBS 50% glycerol |

Available references: (other clones available on request)

| Reference | | Clone | Referred to as (Visco et al) | Format | Isotype | Application tested |
|--------------|---------------|--------------|------------------------------|----------|---------|--|
| 50µg | 100µg | | | | | |
| DDX0070 P-50 | DDX0070 P-100 | H.G27E9B1 | BAB4 | purified | IgG2,k | ELISA (coating) IP |
| DDX0071 P-50 | DDX0071 P-100 | H.G26F6B2.06 | | purified | IgG3 | ELISA, IP |
| DDX0072 P-50 | DDX0072 P-100 | H.G11A9F3.03 | BAB3 | purified | IgG4,k | ELISA (coating) , IP |
| DDX0073 P-50 | DDX0073 P-100 | H.G28C10.01 | BAB5 | purified | IgG4,k | ELISA (coating) , IP |
| DDX0074 P-50 | DDX0074 P-100 | H.G5F2A4.09 | BAB1 | purified | IgG1,k | ELISA, histamine release blocking , WB |
| DDX0075 P-50 | DDX0075 P-100 | H.G3A3C2.04 | | purified | IgG2 | ELISA, IP |
| DDX0076 P-50 | DDX0076 P-100 | H.G17E7A1 | BAB2 | purified | IgG4 | ELISA (coating) , histamine release increase |



Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine release was expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. **A**, when tested individually, only BAB1 inhibits the BetV1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetV1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). **B**, BAB 1 preincubated at 1.5mg/ml with nBetV1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). **C**, the BetV1-induced histamine release inhibition is specific and dose-dependent. nBetV1 was preincubated with successive dilutions of an anti-IL1 α HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of a mixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the basophils from patient J.C.

(Visco et al, *J I* 1996)

Usage recommendation:

- *This monoclonal antibody may be used between 5-20 µg/ml.
- *Optimal dilution should be determined by each laboratory for each application.
- *Coupled antibody: to maintain RT before use

Aliquot storage conditions:

- 20°C. KEEP CONTENTS STERILE: no preservative.**
- Purified antibodies: avoid repeated freeze/thaw cycles.**
- Coupled antibodies: glycerol protects from freezing.**

Not for use in Humans. For research purpose only